Dynamic prediction of metastases after radical prostatectomy for prostate cancer

BJU International

Volumn 108, Issue 11, 2011, Pages 1762-1768

  Inman, Brant A ^a   Frank, Igor ^b   Boorjian, Stephen A ^b   Akornor, Joseph W ^b   Karnes, R Jeffrey ^b   Leibovich, Bradley C ^a   Blute, Michael L ^a   Bergstralh, Eric J ^b  

^a DUKE UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

Author keywords

clinical prediction; metastases; outcome assessment; prostate cancer; prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER INCIDENCE; COHORT ANALYSIS; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEMINAL VESICLE;

AGED; ALGORITHMS; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; POSTOPERATIVE CARE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK ASSESSMENT; SEMINAL VESICLES;

EID: 81255168255     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10208.x     Document Type: Article

References (14)

1. Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H,. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol 2000; 164: 101-5 (Pubitemid 30434268)
2. Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H,. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 2001; 165: 1146-51 (Pubitemid 32210224)
3. Stephenson AJ, Kattan MW, Eastham JA, et al,. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 2006; 24: 3973-8 (Pubitemid 46630746)
4. Kattan MW, Wheeler TM, Scardino PT,. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999; 17: 1499-507 (Pubitemid 29220858)
5. Stephenson AJ, Scardino PT, Eastham JA, et al,. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2005; 23: 7005-12
6. Bauer JJ, Connelly RR, Seterhenn IA, et al,. Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer. J Urol 1998; 159: 929-33 (Pubitemid 28106559)
7. Blute ML, Bergstralh EJ, Iocca A, Scherer B, Zincke H,. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol 2001; 165: 119-25
8. Cooperberg MR, Pasta DJ, Elkin EP, et al,. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 2005; 173: 1938-42 (Pubitemid 40675216)
9. Moul JW, Connelly RR, Lubeck DP, et al. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases. J Urol 2001; 166: 1322-7 (Pubitemid 32862166)
10. D'Amico AV, Whittington R, Malkowicz SB, et al,. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol 1995; 154: 131-8
11. Kalbfleisch JD, Prentice RS,. The Statistical Analysis of Failure Time Data, 2nd edn. Hoboken: John Wiley & Sons, 2002
12. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12 (Pubitemid 39315317)
13. Eisenberger MA, Blumenstein BA, Crawford ED, et al,. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339: 1036-42 (Pubitemid 28457865)
14. Collette L,. Prostate-specific antigen (PSA) as a surrogate end point for survival in prostate cancer clinical trials. Eur Urol 2008; 53: 6-9 (Pubitemid 350166730)